Newronika develops implantable deep brain stimulation systems designed to deliver adaptive therapy for movement disorders. The company’s flagship platform, AlphaDBS, is a closed-loop DBS implant that continuously monitors brain activity to adjust stimulation in real time. Its approach focuses on improving therapeutic precision compared to conventional open-loop DBS systems. Newronika positions its technology within regulated clinical and neurosurgical care pathways.

The technology records neural signals from implanted electrodes to identify biomarkers associated with disease state and symptom fluctuation. These signals are processed onboard to dynamically adapt stimulation parameters, delivering therapy only when needed and in response to real-time brain activity. This closed-loop architecture is designed to improve symptom control while reducing side effects and unnecessary stimulation. The system emphasizes responsiveness, personalization, and long-term stability.

Newronika targets patients with Parkinson’s disease who require implantable neuromodulation for symptom management. AlphaDBS is intended for use in specialized clinical settings under professional supervision. Its positioning reflects broader efforts to advance DBS from static stimulation toward adaptive, brain-responsive therapies that better align with individual neural dynamics.